{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,23]],"date-time":"2026-09-23T11:25:54Z","timestamp":1790162754993,"version":"4.1.0"},"reference-count":64,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2012,12,1]],"date-time":"2012-12-01T00:00:00Z","timestamp":1354320000000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["J. Med. Toxicol."],"published-print":{"date-parts":[[2012,12]]},"DOI":"10.1007\/s13181-012-0270-y","type":"journal-article","created":{"date-parts":[[2012,10,17]],"date-time":"2012-10-17T21:07:10Z","timestamp":1350508030000},"page":"400-407","source":"Crossref","is-referenced-by-count":42,"title":["Abuse-Deterrent Formulations, an Evolving Technology Against the Abuse and Misuse of Opioid Analgesics"],"prefix":"10.1007","volume":"8","author":[{"given":"Tammi","family":"Schaeffer","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2012,12,1]]},"reference":[{"key":"270_CR1","doi-asserted-by":"crossref","first-page":"ES9","DOI":"10.36076\/ppj.2012\/15\/ES9","volume":"15","author":"L Manchikanti","year":"2012","unstructured":"Manchikanti L, Helm Ii S, Fellows B, Janata JW, Pampati V, Grider JS et al (2012) Opioid epidemic in the United States. Pain Physician 15:ES9\u2013ES38","journal-title":"Pain Physician"},{"key":"270_CR2","doi-asserted-by":"publisher","first-page":"2613","DOI":"10.1001\/jama.2008.802","volume":"300","author":"AJ Hall","year":"2008","unstructured":"Hall AJ, Logan JE, Toblin RL, Kaplan JA, Kraner JC, Bixler D et al (2008) Patterns of abuse among unintentional pharmaceutical overdose fatalities. JAMA 300:2613\u201320","journal-title":"JAMA"},{"key":"270_CR3","doi-asserted-by":"crossref","first-page":"S63","DOI":"10.36076\/ppj.2008\/11\/S63","volume":"11","author":"L Manchikanti","year":"2008","unstructured":"Manchikanti L, Singh A (2008) Therapeutic opioids: a ten-year perspective on the complexities and complications of the escalating use, abuse, and nonmedical use of opioids. Pain Physician 11:S63\u201388","journal-title":"Pain Physician"},{"key":"270_CR4","unstructured":"Belouin SJ, Reuter N, Borders-Hemphill V, Mehta H. Prescribing trends for opioids, benzodiazepines, amphetamines, and barbiturates from 1998\u20132007. Available at http:\/\/nac.samhsa.gov\/DTAB\/Presentations\/Aug08\/SeanBelouinDTAB0808.ppt . Accessed on 08\/14\/12"},{"key":"270_CR5","doi-asserted-by":"publisher","first-page":"417","DOI":"10.1037\/a0013636","volume":"16","author":"RA Denisco","year":"2008","unstructured":"Denisco RA, Chandler RK, Compton WM (2008) Addressing the intersecting problems of opioid misuse and chronic pain treatment. Exp Clin Psychopharmacol 16:417\u201328","journal-title":"Exp Clin Psychopharmacol"},{"key":"270_CR6","doi-asserted-by":"publisher","first-page":"662","DOI":"10.1016\/j.jpain.2005.05.004","volume":"6","author":"TJ Cicero","year":"2005","unstructured":"Cicero TJ, Inciardi JA, Munoz A (2005) Trends in abuse of oxycontin and other opioid analgesics in the United States: 2002\u20132004. J Pain 6:662\u201372","journal-title":"J Pain"},{"key":"270_CR7","doi-asserted-by":"publisher","first-page":"103","DOI":"10.1016\/j.drugalcdep.2005.05.009","volume":"81","author":"WM Compton","year":"2006","unstructured":"Compton WM, Volkow ND (2006) Major increases in opioid analgesic abuse in the United States: concerns and strategies. Drug Alcohol Depend 81:103\u20137","journal-title":"Drug Alcohol Depend"},{"key":"270_CR8","unstructured":"Substance Abuse and Mental Health Services Administration, NSDUH Series H-41 (2011) Results from the 2010 National Survey on Drug Use and Health: Summary of National Findings"},{"key":"270_CR9","unstructured":"Anonymous (2011) Epidemic: responding to America\u2019s prescription drug abuse crisis. Available at http:\/\/www.whitehouse.gov\/sites\/default\/files\/ondcp\/issues-content\/prescription-drugs\/rx_abuse_plan.pdf . Accessed on 08\/15\/12"},{"key":"270_CR10","doi-asserted-by":"publisher","first-page":"1601","DOI":"10.1111\/j.1360-0443.1991.tb01754.x","volume":"86","author":"M Farre","year":"1991","unstructured":"Farre M, Cami J (1991) Pharmacokinetic considerations in abuse liability evaluation. Br J Addict 86:1601\u20136","journal-title":"Br J Addict"},{"key":"270_CR11","doi-asserted-by":"publisher","first-page":"255","DOI":"10.1517\/13543780902751622","volume":"18","author":"LR Webster","year":"2009","unstructured":"Webster LR, Bath B, Medve RA (2009) Opioid formulations in development designed to curtail abuse: who is the target? Expert Opin Investig Drugs 18:255\u201363","journal-title":"Expert Opin Investig Drugs"},{"key":"270_CR12","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1007\/s11926-008-0003-z","volume":"10","author":"N Katz","year":"2008","unstructured":"Katz N (2008) Abuse-deterrent opioid formulations: are they a pipe dream? Curr Rheumatol Rep 10:11\u20138","journal-title":"Curr Rheumatol Rep"},{"key":"270_CR13","unstructured":"U.S. Food Drug and Administration, Center for Drug Evaluation and Research (2012) Code of Federal Regulations Title 21, 21CFR320.25"},{"key":"270_CR14","unstructured":"U.S. Food Drug and Administration, Center for Drug Evaluation and Research (2012) Code of Federal Regulations Title 21, 21CFR211"},{"key":"270_CR15","doi-asserted-by":"publisher","first-page":"5","DOI":"10.1080\/J354v20n02_03","volume":"20","author":"SD Passik","year":"2006","unstructured":"Passik SD, Hays L, Eisner N, Kirsh KL (2006) Psychiatric and pain characteristics of prescription drug abusers entering drug rehabilitation. J Pain Palliat Care Pharmacother 20:5\u201313","journal-title":"J Pain Palliat Care Pharmacother"},{"key":"270_CR16","doi-asserted-by":"publisher","first-page":"205","DOI":"10.3109\/00952990.2011.569623","volume":"37","author":"N Katz","year":"2011","unstructured":"Katz N, Dart RC, Bailey E, Trudeau J, Osgood E, Paillard F (2011) Tampering with prescription opioids: nature and extent of the problem, health consequences, and solutions. Am J Drug Alcohol Abuse 37:205\u201317","journal-title":"Am J Drug Alcohol Abuse"},{"key":"270_CR17","first-page":"426","volume":"102","author":"C Baum","year":"1987","unstructured":"Baum C, Hsu JP, Nelson RC (1987) The impact of the addition of naloxone on the use and abuse of pentazocine. Public Health Rep 102:426\u20139","journal-title":"Public Health Rep"},{"key":"270_CR18","doi-asserted-by":"publisher","first-page":"1163","DOI":"10.3109\/10826088709027478","volume":"22","author":"HW Lahmeyer","year":"1987","unstructured":"Lahmeyer HW, Craig RJ (1987) Pentazocine\u2013naloxone: another \u201caddiction-proof\u201d drug of abuse. Int J Addict 22:1163\u20136","journal-title":"Int J Addict"},{"key":"270_CR19","doi-asserted-by":"crossref","unstructured":"Mastropietro DJ, Omidian H (2012) Current approaches in tamper-resistant and abuse-deterrent formulations. Drug Dev Ind Pharm","DOI":"10.3109\/03639045.2012.680468"},{"key":"270_CR20","unstructured":"Anonymous (2012) Oxycontin (oxycodone extended-release) [Product Information]. Available at http:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2012\/022272s011lbl.pdf . Accessed on 08\/17\/12"},{"key":"270_CR21","doi-asserted-by":"crossref","first-page":"423","DOI":"10.6004\/jnccn.2003.0035","volume":"1","author":"L Hays","year":"2003","unstructured":"Hays L, Kirsh KL, Passik SD (2003) Seeking drug treatment for OxyContin abuse: a chart review of consecutive admissions to a substance abuse treatment facility in Kentucky. J Natl Compr Canc Netw 1:423\u20138","journal-title":"J Natl Compr Canc Netw"},{"key":"270_CR22","doi-asserted-by":"publisher","first-page":"1750","DOI":"10.1176\/appi.ajp.2007.07050252","volume":"164","author":"D Carise","year":"2007","unstructured":"Carise D, Dugosh KL, McLellan AT, Camilleri A, Woody GE, Lynch KG (2007) Prescription OxyContin abuse among patients entering addiction treatment. Am J Psychiatry 164:1750\u20136","journal-title":"Am J Psychiatry"},{"key":"270_CR23","unstructured":"Purdue Pharma L.P. (2008) NDA 22-272 Reformulated OxyContin(R), Joint Meeting of the Anesthetic and Life Support Drugs Advisory Committee and Drug Safety and Risk Management Advisory Committee"},{"key":"270_CR24","unstructured":"Purdue. To determine the fed bioequivalence of reformulated OXY tablets and original OxyContin(R) (OXY) tablets In: ClinicalTrials.gov [Internet]. Bethesda (MD): National Library of Medicine (US). Available from: http:\/\/clinicaltrials.gov\/ct2\/show\/NCT01101178 . NLM Identifier: NCT 01101178"},{"key":"270_CR25","unstructured":"Purdue. To determine the fasting bioequivalence of reformulated OXY tablets and original OxyContin\u00ae (OXY) tablets In: ClinicalTrials.gov [Internet]. Bethesda (MD): National Library of Medicine (US). Available from: http:\/\/clinicaltrials.gov\/ct2\/show\/NCT01101165 . NLM Identifier: NCT 01101165."},{"key":"270_CR26","unstructured":"Anonymous (2012) Opana ER (oxymorphone extended-release) [Product information]"},{"key":"270_CR27","doi-asserted-by":"crossref","unstructured":"Vosburg SK, Jones JD, Manubay JM, Ashworth JB, Benedek IH, Comer SD (2012) Assessment of a formulation designed to be crush-resistant in prescription opioid abusers. Drug Alcohol Depend","DOI":"10.1016\/j.drugalcdep.2012.05.013"},{"key":"270_CR28","first-page":"455","volume":"5","author":"IH Benedek","year":"2011","unstructured":"Benedek IH, Jobes J, Xiang Q, Fiske WD (2011) Bioequivalence of oxymorphone extended release and crush-resistant oxymorphone extended release. Drug Des Devel Ther 5:455\u201363","journal-title":"Drug Des Devel Ther"},{"key":"270_CR29","doi-asserted-by":"publisher","first-page":"90","DOI":"10.1016\/j.jpain.2011.10.011","volume":"13","author":"WD Fiske","year":"2012","unstructured":"Fiske WD, Jobes J, Xiang Q, Chang SC, Benedek IH (2012) The effects of ethanol on the bioavailability of oxymorphone extended-release tablets and oxymorphone crush-resistant extended-release tablets. J Pain 13:90\u20139","journal-title":"J Pain"},{"key":"270_CR30","doi-asserted-by":"publisher","first-page":"443","DOI":"10.1007\/s10856-011-4521-2","volume":"23","author":"X Lin","year":"2012","unstructured":"Lin X, Yang S, Gou J, Zhao M, Zhang Y, Qi N et al (2012) A novel risperidone-loaded SAIB-PLGA mixture matrix depot with a reduced burst release: effects of solvents and PLGA on drug release behaviors in vitro\/in vivo. J Mater Sci Mater Med 23:443\u201355","journal-title":"J Mater Sci Mater Med"},{"key":"270_CR31","doi-asserted-by":"publisher","first-page":"359","DOI":"10.1517\/13543784.16.3.359","volume":"16","author":"LR Webster","year":"2007","unstructured":"Webster LR (2007) PTI-821: sustained-release oxycodone using gel-cap technology. Expert Opin Investig Drugs 16:359\u201366","journal-title":"Expert Opin Investig Drugs"},{"key":"270_CR32","first-page":"88","volume":"10","author":"M Zamloot","year":"2010","unstructured":"Zamloot M, Chao W, Kang LL, Ross J, Fu R (2010) Remoxy: a novel formulation of extended-relase oxycodone developed with ORADUR technology. J Appl Res 10:88\u201396","journal-title":"J Appl Res"},{"key":"270_CR33","doi-asserted-by":"publisher","first-page":"193","DOI":"10.5055\/jom.2011.0062","volume":"7","author":"N Friedmann","year":"2011","unstructured":"Friedmann N, Klutzaritz V, Webster L (2011) Efficacy and safety of an extended-release oxycodone (Remoxy) formulation in patients with moderate to severe osteoarthritic pain. J Opioid Manag 7:193\u2013202","journal-title":"J Opioid Manag"},{"key":"270_CR34","doi-asserted-by":"publisher","first-page":"755","DOI":"10.1111\/j.1526-4637.2011.01100.x","volume":"12","author":"N Friedmann","year":"2011","unstructured":"Friedmann N, Klutzaritz V, Webster L (2011) Long-term safety of Remoxy(R) (extended-release oxycodone) in patients with moderate to severe chronic osteoarthritis or low back pain. Pain Med 12:755\u201360","journal-title":"Pain Med"},{"key":"270_CR35","doi-asserted-by":"publisher","first-page":"618","DOI":"10.1111\/j.1526-4637.2011.01093.x","volume":"12","author":"B Setnik","year":"2011","unstructured":"Setnik B, Roland CL, Cleveland JM, Webster L (2011) The abuse potential of Remoxy((R)), an extended-release formulation of oxycodone, compared with immediate- and extended-release oxycodone. Pain Med 12:618\u201331","journal-title":"Pain Med"},{"key":"270_CR36","unstructured":"Rappaport BA FDA Center for drug evaluation and research (2011) Oxecta(R) Division Director\u2019s review and summary basis for approval"},{"key":"270_CR37","unstructured":"Anonymous (2011) Oxecta(R) (oxycodone hydrochloride) [package insert]. Available at http:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2011\/202080s000lbl.pdf . Accessed on 08\/14\/12"},{"key":"270_CR38","unstructured":"Leibowitz MT, Zamora CA, Brzeczko AW, Stark JG (2012) A single-dose, 3-way crossover pharmacokinetic comparison between immediate-release oxycodone hydrochloride with Aversion Technology (IRO-A, Oxecta), IRO-A with niacin, and oxycodone hydrochloride (Roxicodone) in healthy adults under fasting conditions. Am J Ther"},{"key":"270_CR39","unstructured":"Anonymous (2010) Acurox (oxycodone hcl and niacin) NDA 22-451"},{"key":"270_CR40","unstructured":"Anonymous (2012) Embeda (morphine sulfate\/naltrexone) [product information]. Available at http:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2012\/022321s007lbl.pdf . Accessed on 08\/15\/12"},{"key":"270_CR41","doi-asserted-by":"publisher","first-page":"303","DOI":"10.1016\/j.jpain.2009.07.017","volume":"11","author":"N Katz","year":"2010","unstructured":"Katz N, Sun S, Johnson F, Stauffer J (2010) ALO-01 (morphine sulfate and naltrexone hydrochloride) extended-release capsules in the treatment of chronic pain of osteoarthritis of the hip or knee: pharmacokinetics, efficacy, and safety. J Pain 11:303\u201311","journal-title":"J Pain"},{"key":"270_CR42","doi-asserted-by":"publisher","first-page":"777","DOI":"10.2165\/11530800-000000000-00000","volume":"29","author":"J Stauffer","year":"2009","unstructured":"Stauffer J, Setnik B, Sokolowska M, Romach M, Johnson F, Sellers E (2009) Subjective effects and safety of whole and tampered morphine sulfate and naltrexone hydrochloride (ALO-01) extended-release capsules versus morphine solution and placebo in experienced non-dependent opioid users: a randomized, double-blind, placebo-controlled, crossover study. Clin Drug Investig 29:777\u201390","journal-title":"Clin Drug Investig"},{"key":"270_CR43","doi-asserted-by":"publisher","first-page":"999","DOI":"10.1517\/14656566.2011.571208","volume":"12","author":"X Ruan","year":"2011","unstructured":"Ruan X (2011) Sustained-release morphine sulfate with sequestered naltrexone for moderate to severe pain: a new opioid analgesic formulation and beyond. Expert Opin Pharmacother 12:999\u20131001","journal-title":"Expert Opin Pharmacother"},{"key":"270_CR44","unstructured":"Anonymous (2012) EMBEDA Website. Available at http:\/\/embeda.com\/ . Accessed on 08\/15\/12"},{"key":"270_CR45","unstructured":"Anonymous (2011) Suboxone (buprenorphone\/naloxone)[product information]. Available at http:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2011\/020733s007s008lbl.pdf . Accessed on 08\/16\/12"},{"issue":"Suppl 1","key":"270_CR46","doi-asserted-by":"publisher","first-page":"S40","DOI":"10.1016\/j.drugalcdep.2006.01.016","volume":"83","author":"PJ Fudala","year":"2006","unstructured":"Fudala PJ, Johnson RE (2006) Development of opioid formulations with limited diversion and abuse potential. Drug Alcohol Depend 83(Suppl 1):S40\u20137","journal-title":"Drug Alcohol Depend"},{"key":"270_CR47","doi-asserted-by":"publisher","first-page":"949","DOI":"10.1056\/NEJMoa022164","volume":"349","author":"PJ Fudala","year":"2003","unstructured":"Fudala PJ, Bridge TP, Herbert S, Williford WO, Chiang CN, Jones K et al (2003) Office-based treatment of opiate addiction with a sublingual-tablet formulation of buprenorphine and naloxone. N Engl J Med 349:949\u201358","journal-title":"N Engl J Med"},{"key":"270_CR48","doi-asserted-by":"publisher","first-page":"230","DOI":"10.1007\/s002130000637","volume":"154","author":"KB Stoller","year":"2001","unstructured":"Stoller KB, Bigelow GE, Walsh SL, Strain EC (2001) Effects of buprenorphine\/naloxone in opioid-dependent humans. Psychopharmacology (Berl) 154:230\u201342","journal-title":"Psychopharmacology (Berl)"},{"key":"270_CR49","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/S0376-8716(98)00008-8","volume":"50","author":"PJ Fudala","year":"1998","unstructured":"Fudala PJ, Yu E, Macfadden W, Boardman C, Chiang CN (1998) Effects of buprenorphine and naloxone in morphine-stabilized opioid addicts. Drug Alcohol Depend 50:1\u20138","journal-title":"Drug Alcohol Depend"},{"key":"270_CR50","doi-asserted-by":"publisher","first-page":"484","DOI":"10.1007\/BF00212842","volume":"94","author":"KL Preston","year":"1988","unstructured":"Preston KL, Bigelow GE, Liebson IA (1988) Buprenorphine and naloxone alone and in combination in opioid-dependent humans. Psychopharmacology (Berl) 94:484\u201390","journal-title":"Psychopharmacology (Berl)"},{"key":"270_CR51","doi-asserted-by":"publisher","first-page":"68","DOI":"10.1080\/00952990802585406","volume":"35","author":"RD Bruce","year":"2009","unstructured":"Bruce RD, Govindasamy S, Sylla L, Kamarulzaman A, Altice FL (2009) Lack of reduction in buprenorphine injection after introduction of co-formulated buprenorphine\/naloxone to the Malaysian market. Am J Drug Alcohol Abuse 35:68\u201372","journal-title":"Am J Drug Alcohol Abuse"},{"key":"270_CR52","doi-asserted-by":"publisher","first-page":"75","DOI":"10.1016\/j.drugalcdep.2006.09.012","volume":"88","author":"H Alho","year":"2007","unstructured":"Alho H, Sinclair D, Vuori E, Holopainen A (2007) Abuse liability of buprenorphine-naloxone tablets in untreated IV drug users. Drug Alcohol Depend 88:75\u20138","journal-title":"Drug Alcohol Depend"},{"key":"270_CR53","doi-asserted-by":"publisher","first-page":"16","DOI":"10.1186\/1747-597X-3-16","volume":"3","author":"K Simojoki","year":"2008","unstructured":"Simojoki K, Vorma H, Alho H (2008) A retrospective evaluation of patients switched from buprenorphine (Subutex) to the buprenorphine\/naloxone combination (Suboxone). Subst Abuse Treat Prev Policy 3:16","journal-title":"Subst Abuse Treat Prev Policy"},{"key":"270_CR54","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.tox.2007.04.005","volume":"236","author":"KM Wu","year":"2007","unstructured":"Wu KM, Farrelly JG (2007) Regulatory perspectives of Type II prodrug development and time-dependent toxicity management: nonclinical Pharm\/Tox analysis and the role of comparative toxicology. Toxicology 236:1\u20136","journal-title":"Toxicology"},{"key":"270_CR55","doi-asserted-by":"publisher","first-page":"410","DOI":"10.1177\/0269881108093841","volume":"23","author":"DR Jasinski","year":"2009","unstructured":"Jasinski DR, Krishnan S (2009) Human pharmacology of intravenous lisdexamfetamine dimesylate: abuse liability in adult stimulant abusers. J Psychopharmacol 23:410\u20138","journal-title":"J Psychopharmacol"},{"key":"270_CR56","unstructured":"Anonymous extended-release (ER) and long-acting (LA) opioid analgesics Risk Evaluation and mitigation Strategy (REMS). Available at http:\/\/www.fda.gov\/downloads\/Drugs\/DrugSafety\/PostmarketDrugSafetyInformationforPatientsandProviders\/UCM311290.pdf . Accessed on 07\/30\/12"},{"key":"270_CR57","unstructured":"U.S. Food Drug and Administration, Center for Drug Evaluation and Research (2010) Guidance for industry: assessment of abuse potential drugs"},{"key":"270_CR58","unstructured":"Anonymous (2007) Title 21 United States Code Controlled Substances Act. Available at http:\/\/www.deadiversion.usdoj.gov\/21cfr\/21usc\/812.htm . Accessed on 08\/04\/12"},{"key":"270_CR59","doi-asserted-by":"crossref","unstructured":"Turk DC, O\u2019Connor AB, Dworkin RH, Chaudhry A, Katz NP, Adams EH, et al. (2012) Research design considerations for clinical studies of abuse-deterrent opioid analgesics: IMMPACT recommendations. Pain","DOI":"10.1016\/j.pain.2012.05.029"},{"key":"270_CR60","doi-asserted-by":"publisher","first-page":"187","DOI":"10.1056\/NEJMc1204141","volume":"367","author":"TJ Cicero","year":"2012","unstructured":"Cicero TJ, Ellis MS, Surratt HL (2012) Effect of abuse-deterrent formulation of OxyContin. N Engl J Med 367:187\u20139","journal-title":"N Engl J Med"},{"key":"270_CR61","unstructured":"Karst KR (2012) STOPP act would establish new requirements for tamper-resistant drugs. Available at http:\/\/www.fdalawblog.net\/fda_law_blog_hyman_phelps\/2012\/07\/stopp-act-would-establish-new-requirements-for-tamper-resistant-drugs.html . Accessed on 08\/28\/12"},{"key":"270_CR62","unstructured":"Anonymous (2012) Defeating the new Opana for snorting. Available at http:\/\/www.topix.com\/forum\/drug\/oxycontin\/T7TFK45DARQ6L7QRS . Accessed on 08\/28\/12"},{"key":"270_CR63","unstructured":"Anonymous (2012) Defeating the new \u201cOP\u201d oxycontin. Available at http:\/\/www.topix.com\/forum\/drug\/oxycontin\/TO8T6EEQ3IBMK99GK\/p143 . Accessed on 08\/28\/12"},{"key":"270_CR64","unstructured":"Anonymous (2012) \u201cOXECTA\u201d will soon be replacing all OXYCODONE I.R. Available at http:\/\/www.topix.com\/forum\/drug\/oxycontin\/TO8T6EEQ3IBMK99GK\/p143 . Accessed on 08\/28\/12"}],"container-title":["Journal of Medical Toxicology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s13181-012-0270-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s13181-012-0270-y\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s13181-012-0270-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s13181-012-0270-y","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,1,30]],"date-time":"2022-01-30T09:59:26Z","timestamp":1643536766000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s13181-012-0270-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2012,12]]},"references-count":64,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2012,12]]}},"alternative-id":["270"],"URL":"https:\/\/doi.org\/10.1007\/s13181-012-0270-y","relation":{},"ISSN":["1556-9039","1937-6995"],"issn-type":[{"value":"1556-9039","type":"print"},{"value":"1937-6995","type":"electronic"}],"subject":[],"published":{"date-parts":[[2012,12]]}}}